Company research
Coya Therapeutics, Inc.
CIK 1835022Updated Sep 26, 2026
SecurityCOYA · NASDAQ · equity
COYA price & chart
Loading TradingView…
NASDAQ:COYA on TradingView ↗About the company
Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases. This cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system.
In the news
Recent filings
Other Events
Items 8.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Submission of Matters to a Vote of Security Holders
Items 5.07
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 49,950,245Source | 44,347,016Source | 41,262,274Source | 8,395,566Source |
| Property, Plant and Equipment, NetUSD | 11,227Source | 38,588Source | 65,949Source | 93,310Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 46,822,786Source | 38,339,762Source | 32,626,768Source | 5,933,702Source |
| Assets, CurrentUSD | 49,939,018Source | 44,308,428Source | 41,196,325Source | 7,184,966Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,116,232Source | 5,968,666Source | 1,069,557Source | 1,251,264Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 6,922,015Source | 4,769,921Source | 5,626,665Source | 16,789,111Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | — | — | 8,793,637Source |
| Common Stock, Value, IssuedUSD | 2,094Source | 1,671Source | 1,441Source | 259Source |
| Additional Paid in CapitalUSD | 104,989,413Source | 80,312,594Source | 61,501,801Source | 681,106Source |
| Retained Earnings (Accumulated Deficit)USD | -61,963,277Source | -40,737,170Source | -25,856,383Source | -17,868,547Source |
| Stockholders' Equity Attributable to ParentUSD | 43,028,230Source | 39,577,095Source | 35,635,609Source | -8,393,545Source |
| Liabilities and EquityUSD | 49,950,245Source | 44,347,016Source | 41,262,274Source | 8,395,566Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 5,871,891Source | 3,824,474Source | 5,051,980Source | 3,823,631Source |
| Accounts Payable, CurrentUSD | 1,061,122Source | 1,588,128Source | 1,155,656Source | 1,815,270Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 3,612,913Source | 1,388,060Source | 2,973,215Source | 2,008,361Source |
| Deferred Revenue, CurrentUSD | 1,197,856Source | 848,286Source | 923,109Source | — |
| Deferred Tax Liabilities, NetUSD | — | — | — | 60Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -21,226,107Source | -14,880,787Source | -7,987,836Source | -12,244,776Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 4,290,315Source | 2,663,539Source | 872,248Source | 207,346Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -527,006Source | 477,450Source | 298,816Source | 845,284Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -10,739,301Source | -10,288,822Source | -11,188,811Source | -7,239,354Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -1,164,602Source | -25,000Source | -543,186Source | -525,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 20,386,927Source | 16,026,816Source | 38,425,063Source | 9,357,878Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | -730,581Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 4,290,315Source | 2,663,539Source | 872,248Source | 207,346Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | 997,367Source |
| DepreciationUSD | 27,361Source | 27,361Source | 27,361Source | 27,361Source |
| General and Administrative ExpenseUSD | 11,449,466Source | 8,885,757Source | 7,833,481Source | 4,847,080Source |
| Income Tax Expense (Benefit)USD | 3,089Source | -720,287Source | 723,852Source | — |
| Net Income (Loss) Attributable to ParentUSD | -21,226,107Source | -14,880,787Source | -7,987,836Source | -12,244,776Source |
| Operating ExpensesUSD | 30,500,978Source | 20,803,772Source | 13,905,555Source | 9,811,939Source |
| Other Nonoperating Income (Expense)USD | 1,332,207Source | 1,648,637Source | 639,365Source | 63,673Source |
| Proceeds from Issuance of Common StockUSD | 20,348,653Source | 14,004,381Source | — | — |
| Proceeds from Stock Options ExercisedUSD | 38,274Source | 1,975Source | 89,947Source | 158Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 7,945,753Source | 3,554,061Source | 6,002,206Source | — |
| Operating Income (Loss)USD | -22,555,225Source | -17,249,711Source | -7,903,349Source | -9,811,939Source |
| Other Nonoperating Income (Expense)USD | 1,332,207Source | 1,648,637Source | 639,365Source | 63,673Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -21,223,018Source | -15,601,074Source | -7,263,984Source | — |
| Income Tax Expense (Benefit)USD | 3,089Source | -720,287Source | 723,852Source | — |
| Net Income (Loss) Attributable to ParentUSD | -21,226,107Source | -14,880,787Source | -7,987,836Source | -12,244,776Source |
| Earnings Per Share, BasicUSD per share | -1.27Source | -0.98Source | -0.79Source | -4.73Source |
| Earnings Per Share, DilutedUSD per share | -1.27Source | -0.98Source | -0.79Source | -4.73Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 16,730,274Source | 15,238,919Source | 10,163,850Source | 2,590,173Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 16,730,274Source | 15,238,919Source | 10,163,850Source | 2,590,173Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 11,449,466Source | 8,885,757Source | 7,833,481Source | 4,847,080Source |
| Labor and Related ExpenseUSD | 3,100,930Source | 2,685,556Source | — | — |
| Operating ExpensesUSD | 30,500,978Source | 20,803,772Source | 13,905,555Source | 9,811,939Source |
| Other General and Administrative ExpenseUSD | 5,546,363Source | 4,611,534Source | — | — |
Filing attachments
coya-ex99_1.htm · 8-K · 2026-08-11
EX-99.1 2 coya-ex99_1.htm EX-99.1 EX-99.1 Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update HOUSTON, TX., August 11, 2026 (BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces its financial results for the quarter ended June 30, 2026 and provides a corporate …
Read attachment ↗coya-ex99_1.htm · 8-K · 2026-05-12
EX-99.1 2 coya-ex99_1.htm EX-99.1 EX-99.1 Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update HOUSTON, TX., May 12, 2026 (BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces its financial results for the quarter ended March 31, 2026 and provides a corporate upd…
Read attachment ↗d104763dex991.htm · 8-K · 2026-04-02
EX-99.1 3 d104763dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director Howard Berman, Ph. D., the Company’s Founder and current Executive Chairman and Director, has stepped down from his roles, following the CEO transition process initiated in November 2024. ────────────────────────────────────────────────────────────────────────────────────────────────────────────── Mark H. Pavao, a se…
Read attachment ↗